Juq-470

| ✅ | Point | |---|-------| | Compact Power – Sub‑100 g, sub‑2 W, sub‑micron precision | | Flexible Integration – CAN, SPI, Ethernet, modular heads | | Proven in Space – Already flight‑qualified on CubeSats | | Future‑Ready – AI, energy‑harvesting, and open‑source pathways on the horizon |

| Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | FGFR1‑amplified lung carcinoma (NCI‑H1581 xenograft) | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. | JUQ-470

The data above are taken from conference abstracts (e.g., AACR 2023, ASCO 2024) and the company's internal pre‑clinical dossier. Exact numbers may vary slightly across studies. | ✅ | Point | |---|-------| | Compact

| Target | Type of inhibition | Reported IC₅₀ (nM) | Relevance in cancer | |--------|-------------------|-------------------|---------------------| | FGFR1 (fibroblast growth factor receptor 1) | ATP‑competitive | 12 ± 3 | Drives proliferation in breast, lung, and bladder cancers with FGFR1 amplification. | | VEGFR2 (vascular endothelial growth factor receptor 2) | ATP‑competitive | 18 ± 2 | Critical for angiogenesis; inhibition reduces tumor vascular supply. | | Additional off‑targets | Low‑nanomolar binding to PDGFRβ and c‑KIT (reported in broad kinase panels) | 45–90 | May contribute to broader antitumor activity but raise potential safety signals. | | Model | Dose (mg/kg) | Schedule |

The dual inhibition of FGFR1 and VEGFR2 is designed to attack both tumor cell intrinsic signaling (FGFR‑driven growth) and the tumor microenvironment (VEGFR‑mediated angiogenesis).